Bruceine A
Based on 4 publication(s) in Google Scholar
Bruceine A (Dihydrobrusatol) is a natural quassinoid. Bruceine A is an inhibitor of parasites, NF-κB, and PFKFB4 (Kd: 44 nM). Bruceine A is an activator of P38α MAPK. Bruceine A has antiparasitic activity. Bruceine A has antitumor activity and inhibits cancer cell migration. Bruceine A blocks the cell cycle and induces apoptosis. Bruceine A can be used in parasites, pancreatic cancer, and breast cancer research.
For research use only. We do not sell to patients.
- Purity : 99.89%
- CAS No.: 25514-31-2
- Formula: C26H34O11
- Molecular Weight:522.54
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Bruceine A
MoreAll Parasite Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
PFKFB4 44 nM (Kd) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
0.082 μM
Compound: 9b
|
Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by WST-1 assay
Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by WST-1 assay
|
[PMID: 33289552] |
| HeLa | IC50 |
1.1 μM
Compound: 9b
|
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
|
[PMID: 33289552] |
| HL-60 | IC50 |
0.13 μM
Compound: 9b
|
Antiproliferative activity against human HL-60 cells
Antiproliferative activity against human HL-60 cells
|
[PMID: 33289552] |
| HT-29 | IC50 |
3.1 μM
Compound: 9b
|
Antiproliferative activity against human HT-29 cells
Antiproliferative activity against human HT-29 cells
|
[PMID: 33289552] |
| LNCaP | ED50 |
96 nM
Compound: 7
|
Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay
Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay
|
[PMID: 19026551] |
| Lu1 | ED50 |
79 nM
Compound: 7
|
Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay
Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay
|
[PMID: 19026551] |
| MCF7 | ED50 |
1.5 nM
Compound: 7
|
Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay in presence of 43 uM (-)-hydnocarpin
Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay in presence of 43 uM (-)-hydnocarpin
|
[PMID: 19026551] |
| MCF7 | ED50 |
15 nM
Compound: 7
|
Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay
|
[PMID: 19026551] |
| MCF7 | IC50 |
0.18 μM
Compound: 9b
|
Cytotoxicity against human MCF-7 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human MCF-7 cells incubated for 72 hrs by MTT assay
|
[PMID: 33289552] |
| MDA-MB-231 | IC50 |
0.23 μM
Compound: 9b
|
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
|
[PMID: 33289552] |
In Vitro
Bruceine A (6.25-100 nM/0.08-20 μM, 24-72 h) inhibits the viability of pancreatic cancer cell lines MIA PaCa-2, SW1990, PANC-1 and AsPC-1 cells in a time- and dose-dependent manner[1].
Bruceine A (12.5-50 nM, 24 h) increases the percentage of MIA PaCa-2 cells in the G1 phase[1].
Bruceine A (12.5-50 nM, 24 h) induces apoptosis of MIA PaCa-2 cells in a dose-dependent manner[1].
Bruceine A (12.5-50 nM, 24 h) inhibits the mRNA expression level of PFKFB4 in MIA PaCa-2 cells[1].
Bruceine A (30-120 nM/0.3-1.2 μM, 24-48 h) inhibits the viability of MDA-MB-231 (IC50: 78.4 nM) and 4T1 (IC50: 524.6 nM) cells in triple negative breast cancer (TNBC) cell lines[2].
Bruceine A (7.5-30 nM/150-450 nM, 48 h) causes G0-G1 cell cycle arrest in MDA-MB-231 and 4T1 cells[2].
Bruceine A (60-240 nM/0.6-2.4 μM, 48 h) induces apoptosis (58.37% and 56.21%) in MDA-MB-231 and 4T1 cells in a dose-dependent manner[2].
Bruceine A (30-120 nM/0.3-1.2 μM, 24 h) inhibits the migration of MDA-MB-231 and 4T1 cells in a concentration-dependent manner[2].
Bruceine A (72 h) inhibits the activity of Entamoeba histolytica (IC50: 222.0 nM), Plasmodium falciparum (IC50: 21.0 nM), Babesia gibbsii (IC50: 7.7 nM), and Trypanosoma evansi (IC50: 2.9 nM)[3].
Bruceine A (2 h) inhibits the activity of NF-κB in Hela cells (IC50: 5.3 μg/mL)[4].
Bruceine A activates the p38α MAPK signaling pathway in MIA PaCa-2 cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MIA PaCa-2 cells; SW1990, PANC-1 and AsPC-1 cells
-
Concentration:6.25, 12.5, 25, 50 and 100 nM; 0.08, 0.31, 1.25, 5 and 20 μM
-
Incubation Time:24, 48 and 72 h
-
Result:Inhibited the growth of adenocarcinoma cell lines MIA PaCa-2, SW1990, PANC-1, and AsPC-1 cells.
-
Cell Line:MIA PaCa-2 cells
-
Concentration:12.5, 25 and 50 nM
-
Incubation Time:24 h
-
Result:Down-regulated protein levels of CDK4, CDK6 and Cyclin D1.
Increased the expression of apoptosis-related proteins cleaved caspase3, cleaved caspase9, and cleaved PARP.
-
Cell Line:MIA PaCa-2 cells
-
Concentration:12.5, 25 and 50 nM
-
Incubation Time:24 h
-
Result:Inhibited the mRNA expression level of PFKFB4 in MIA PaCa-2 cells.
-
Cell Line:MDA-MB-231 and 4T1 cells
-
Concentration:24 and 48 h
-
Incubation Time:24, 48 and 72 h
-
Result:Inhibits the proliferation activity of MDA-MB-231 and 4T1 cells.
-
Cell Line:MDA-MB-231 and 4T1 cells
-
Concentration:30, 60 and 120 nM; 0.3, 0.6 and 1.2 μM
-
Incubation Time:24 h
-
Result:Down-regulated the protein expression levels of CDK4, CDK6 and Cyclin D1.
Up-regulated the protein expression levels of Bax, Cyt C and Cleaved-Caspase-3/9.
Down-regulated the protein expression levels of Bcl-2, PARP and Caspase-3/9.
Down-regulated the protein expression levels of MMP2 and MMP9.
In Vivo
Bruceine A (2-4 mg/kg, i.p., once every day for 2 weeks) has antitumor activity in mice with 4T1 xenograft tumor model[2].
Bruceine A (2-4 mg/kg, i.p., once every day for 17 d) inhibits lung metastasis in mice with 4T1-luc breast cancer lung metastasis model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c athymic male nude mice pancreatic cancer model (6 weeks old)[1]
-
Dosage:0.02, 0.1, 0.5 mg/kg
-
Administration:Intravenous injection (i.v.), once every day for 10 d
-
Result:Inhibited tumor growth.
Reduced protein levels of PFKFB4 and GSK3β in tumor tissues.
Reduced PCNA and Ki67 positive cells.
-
Animal Model:4T1 xenograft tumor model (female BALB/c mice, 6-8 weeks old, 18-20 g)[2]
-
Dosage:2 and 4 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once every day for 2 weeks
-
Result:Inhibited tumor growth.
Reduced Ki67 proliferation marker staining and p-MEK staining.
-
Animal Model:4T1-luc breast cancer lung metastasis model (female BALB/c mice, 6-8 weeks old, 18-20 g)[2]
-
Dosage:2 and 4 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once every day for 17 d
-
Result:Inhibited lung metastasis.
Chemical Information
-
CAS No. 25514-31-2
-
Appearance Solid
-
Molecular Weight 522.54
-
Formula C26H34O11
-
Color White to off-white
-
SMILES
O=C([C@@]1([C@H]([C@H](O)[C@]2([H])[C@]3(C4)C)O)[C@@]([C@H](C5=O)OC(CC(C)C)=O)([H])[C@@]2([C@@](O5)([H])C[C@@]3([H])C(C)=C(O)C4=O)CO1)OC
-
Synonyms
Dihydrobrusatol; NSC310616
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nat Microbiol
2023 Jan;8(1):121-134. PMID: 36604514 -
Biochem Pharmacol
Quassinoid analogs exert potent antitumor activity via reversible protein biosynthesis inhibition in human colorectal cancer. [Abstract]2023 Jun:212:115564. PMID: 37116665 -
Chem Biol Drug Des
Bruceine A Suppresses Triple-Negative Breast Cancer Growth and Metastasis by Inducing GPX4-Dependent Ferroptosis via Ubiquitin-Proteasome-Mediated Degradation. [Abstract]2026 Apr;107(4):e70293. PMID: 41967461 -
Chem Biol Drug Des
Bruceine A inhibited breast cancer proliferation and metastasis by inducing autophagy via targeting PI3K-AKT signaling pathway. [Abstract]2024 Jan;103(1):e14398. PMID: 38010171
Solvent & Solubility
In Vitro:
DMSO : ≥ 25 mg/mL (47.84 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.98 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Neural Crest/Neuronal Cell Migration Explant Assay
Neural crest (NC) and neuronal cell migration explant assays are in vitro systems in which neural tube-derived tissues are cultured to allow premigratory or newly emigrated neural crest cells to undergo epithelial-to-mesenchymal transition (EMT), migrate away from the explant, and form a measurable radial outgrowth that reflects migratory capacity and environmental responsiveness. These assays typically quantify migration by measuring the expansion of cell outgrowth from neural tube or neural plate border explants over time, often comparing early and later timepoints to derive a migration index such as a radius ratio, which reflects net cell dispersal from the explant core. Neural tube explant cultures preserve key aspects of neural crest behavior, including EMT, migration, and early differentiation, making them suitable for assessing intrinsic migratory ability and extrinsic cue dependence. However, studies emphasize that migratory outgrowth from neural tube explants may include non-n
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
3D Collagen/Hydrogel Matrix Migration Assay
The 3D collagen/hydrogel matrix migration assay is based on embedding cells within or on top of a fibrillar collagen type I-rich three-dimensional matrix to model in vivo-like extracellular matrix (ECM) architecture, enabling analysis of cell migration through a physically and biochemically relevant scaffold. In contrast to 2D migration systems, cells in 3D matrices interact with fibrillar collagen networks, requiring coordinated adhesion remodeling and proteolytic or non-proteolytic deformation mechanisms to move through confined spaces, thereby providing a more physiologically relevant readout of invasive and migratory behavior in tissue-like environments. Cell movement in 3D collagen matrices is typically quantified by tracking single-cell trajectories, invasion depth, or matrix penetration over time, reflecting combined effects of cytoskeletal dynamics, cell-ECM adhesion turnover, and ECM remodeling. These systems are widely used to study tumor cell invasion and stromal cell motili
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
Purity & Documentation
-
Data Sheet (289 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhang P, et al. Bruceine A induces cell growth inhibition and apoptosis through PFKFB4/GSK3β signaling in pancreatic cancer. Pharmacol Res. 2021 Jul;169:105658. [Content Brief]
[2]. Li X, et al. Bruceine A: Suppressing metastasis via MEK/ERK pathway and invoking mitochondrial apoptosis in triple-negative breast cancer. Biomed Pharmacother. 2023 Dec;168:115784. [Content Brief]
[3]. Bawm S, et al. In vitro antitrypanosomal activities of quassinoid compounds from the fruits of a medicinal plant, Brucea javanica. Vet Parasitol. 2008 Dec 20;158(4):288-94. [Content Brief]
[4]. Kim JA, et al. NF-kappaB inhibitors from Brucea javanica exhibiting intracellular effects on reactive oxygen species. Anticancer Res. 2010 Sep;30(9):3295-300. [Content Brief]
[5]. Lu C, et al. A novel P38α MAPK activator Bruceine A exhibits potent anti-pancreatic cancer activity. Comput Struct Biotechnol J. 2021 Jun 6;19:3437-3450. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9137 mL | 9.5686 mL | 19.1373 mL | 47.8432 mL |
| 5 mM | 0.3827 mL | 1.9137 mL | 3.8275 mL | 9.5686 mL | |
| 10 mM | 0.1914 mL | 0.9569 mL | 1.9137 mL | 4.7843 mL | |
| 15 mM | 0.1276 mL | 0.6379 mL | 1.2758 mL | 3.1895 mL | |
| 20 mM | 0.0957 mL | 0.4784 mL | 0.9569 mL | 2.3922 mL | |
| 25 mM | 0.0765 mL | 0.3827 mL | 0.7655 mL | 1.9137 mL | |
| 30 mM | 0.0638 mL | 0.3190 mL | 0.6379 mL | 1.5948 mL | |
| 40 mM | 0.0478 mL | 0.2392 mL | 0.4784 mL | 1.1961 mL |
Keywords
- Bruceine A
- 25514-31-2
- Dihydrobrusatol
- NSC310616
- NSC310616
- NSC 310616
- NSC-310616
- Parasite
- NF-κB
- p38 MAPK
- Phosphatase
- Apoptosis
- Antitumor
- Antiparasitic
- MIA PaCa-2
- MDA-MB-231
- 4T1
- BALB/c nude mouse pancreatic cancer model
- 4T1 xenograft tumor model
- 4T1-luc breast cancer lung metastasis model
- pancreatic cancer
- breast cancer
- Inhibitor
- inhibitor
- inhibit